Article

Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells.

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Molecular Medicine Reports (Impact Factor: 1.17). 04/2012; 5(4):1068-74. DOI: 10.3892/mmr.2012.753
Source: PubMed

ABSTRACT Recent epidemiological studies have demonstrated that metformin lowers the risk of several types of cancer in diabetic patients. Matrix metalloproteinases (MMPs) play a crucial role in the degradation of the vascular basement membrane extracellular matrix proteins, thereby promoting endothelial cell invasion, migration and angiogenesis in the incidence and progression of tumors. The aim of this study was to investigate the effects of metformin on human umbilical vein endothelial cell (HUVEC) proliferation and migration, as well as on MMP-2 and MMP-9 expression. Cell proliferation was determined by cell counting and MTT colorimetric assays. Cell migration was assessed by the wound repair method. Quantitative real-time reverse transcription PCR was performed to quantify the mRNA expression of MMPs. Metformin at concentrations of 0.5-3.0 mM effectively reduced the number of endothelial cells by 5.5-55%, without being cytotoxic to the cells. Similarly, cell proliferation and migration were markedly inhibited by metformin. In addition, treatment with metformin demonstrated a strong (P<0.001) suppressive effect on the mRNA levels of MMP-2 and -9 in the endothelial cells. The inhibitory effects of metformin on endothelial cell number, migration, and MMP expression were reversed partially by compound C, which is an inhibitor of AMP-activated protein kinase (AMPK). The present study reports that metformin considerably inhibited the proliferation, migration, and MMP-2 and -9 expression of HUVECs, and the effect was partially AMPK-dependent. The obtained findings provide a molecular rationale, whereby metformin can exert anticancer effects.

0 Bookmarks
 · 
123 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently, epithelial-mesenchymal transition (EMT) has been implicated in human pathology, including fibrosis and cancer metastasis. In this study, we investigated the inhibitory effects of green tea seed (GTS) on the EMT process and migration using the human breast cancer cell line, MDA-MB231. Pretreatment with GTS significantly inhibited migration of breast cancer cells, as measured by monolayer scratch assay. GTS treatment clearly decreased vimentin (a mesenchymal marker) and focal adhesion kinase (FAK) mRNA expression, while E-cadherin (an epithelial marker) expression was significantly increased. Furthermore, GTS also reduced matrix metalloproteinase (MMP)-2 and -9. Taken together, our results demonstrated that GTS inhibits migration of breast cancer cells by suppressing the EMT process via reduction of MMP activities and FAK mRNA expression. Based on these findings, we speculate that GTS might be a potential agent for inhibition of breast cancer cell migration.
    Food science and biotechnology 08/2013; 22(4). · 0.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: N6-isopentenyladenosine (iPA), an end product of the mevalonate pathway with an isopentenyl chain, is already known to exert a suppressor effect against various tumors. In this work, we investigated whether iPA also directly interferes with the angiogenic process, which is fundamental to tumor growth and progression. To this end, using human umbilical vein endothelial cells (HUVECs) as a suitable in vitro model of angiogenesis, we evaluated their viability, proliferation, migration, invasion, tube formation in response to iPA, and molecular mechanisms involved. Data were corroborated in mice by using a gel plug assay. iPA dose- and time-dependently inhibited all the neoangiogenesis stages, with an IC50 of 0.98 μM. We demonstrated for the first time, by liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS), that iPA was monophosphorylated into 5'-iPA-monophosphate (iPAMP) by the adenosine kinase (ADK) inside the cells. iPAMP is the active form that inhibits angiogenesis through the direct activation of AMP-kinase (AMPK). Indeed, all effects were completely reversed by pretreatment with 5-iodotubercidin (5-Itu), an ADK inhibitor. The isoprenoid intermediate isopentenyl pyrophosphate (IPP), which shares the isopentenyl moiety with iPA, was ineffective in the inhibition of angiogenesis, thus showing that the iPA structure is specific for the observed effects. In conclusion, iPA is a novel AMPK activator and could represent a useful tool for the treatment of diseases where excessive neoangiogenesis is the underlying pathology.- Pisanti, S., Picardi, P., Ciaglia, E., Margarucci, L., Ronca, R., Giacomini, A., Malfitano, A. M., Casapullo, A., Laezza, C., Gazzerro, P., Bifulco, M. Anti-angiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end-product, mediated by AMPK activation.
    The FASEB Journal 11/2013; · 5.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The biguanide metformin is used in type 2 diabetes management and has gained significant attention as a potential cancer preventive agent. Angioprevention represents a mechanism of cancer prevention, yet conflicting data concerning the anti-angiogenic action of metformin have emerged. Here we clarify some of the contradictory effects of metformin on endothelial cells and angiogenesis, using in vitro and in vivo assays combined with transcriptomic and protein array approaches. Metformin inhibits formation of capillary-like networks by endothelial cells; this effect is partially dependent on the energy sensor AMPK as shown by siRNA knock-down. Gene expression profiling of HUVEC revealed a paradoxical modulation of several angiogenesis-associated genes and proteins by metformin, with short term induction of VEGF, COX2 and CXCR4 at mRNA levels and down-regulation of ADAMTS1. Antibody array analysis shows an essentially opposite regulation of numerous angiogenesis-associated proteins in endothelial and breast cancer cells. Endothelial production of the cytochrome P450 member CYP1B1 is up-regulated by tumor cell supernatants in an AMPK dependent manner, metformin blocks this effect. Metformin inhibits VEGF-dependent activation of ERK1/2, and the inhibition of AMPK activity abrogates this event. Metformin hinders angiogenesis in matrigel pellets in vivo, contrasts the microvessel density increase observed in obese mice on a high fat diet, down-regulating the number of white adipose tissue endothelial precursor cells. Our data show that metformin has an anti-angiogenic activity in vitro and in vivo associated with a contradictory short-term enhancement of pro-angiogenic mediators, as well as with a differential regulation in endothelial and breast cancer cells.
    Carcinogenesis 01/2014; · 5.64 Impact Factor

Full-text

Download
29 Downloads
Available from
Jun 5, 2014